Pazufloxacin Toyama Chemical Co

Current Opinion in Investigational Drugs

Volumn 1, Issue 1, 2000, Pages 52-57

  Johnson, A P ^a  

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PAZUFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; TOSUFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; EAR NOSE THROAT DISEASE; GRAM NEGATIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RASH; RESPIRATORY TRACT DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION; UROGENITAL TRACT DISEASE;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; FLUOROQUINOLONES; HUMANS; OXAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033761693     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. T-3761. T-372 (monomesylate)
2. Pharmacokinetics and safety of T-3762 in healthy volunteers
3. Cytotoxicity and mutagenicity studies of T-3761
4. Phototoxicity and photoallergenicity tests of T-3761
5. Three months oral repeated dose toxicity of T-3761 in beagle dogs
6. Three months oral repeated dose toxicity of T-3761 in rats
7. Single administration toxicity studies of T-3761 in mice, rats, and dogs
8. General pharmacology of T-3761, a new orally quinolone antibacterial agent: (2) Effect on the respiratory and cardiovascular systems, autonomic nervous system and other functions
9. General pharmacology of T-3761, a new oral quinolone antibacterial agent: (1) Effect on the central nervous system
10. 14C]T-3761 in rats and mice
11. Study of metabolism of T-3761 in animals
12. Absorption, distribution, metabolism and excretion of T-3761, a new quinolone derivative, in experimental animals
13. Determination of T-3761 in body fluids by high-performance liquid chromatography
14. Microbiology assay method for T-3761 concentration in body fluids
15. In vitro antimycobacterial activity of a new quinolone, T-3761
16. Practical synthesis of T-3761 (S)-10-(1-aminocyclo-propyl)-9-fluoro-3-methyl-1-oxo-2,3-dihydro-7 H-pyrido[1,2,3,-de]-1,4-benzoxazine-6-carboxylic acid
17. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative
18. In vitro and in vivo antibacterial activity of T-3761, a new fluoroquinolone
19. Effect of T-3762 on plasma histamine concentration and blood pressure in dogs
20. Drug development pipeline: Pazufloxacin
21. Quinolones and PAR still excite
22. Study of the clinical effects of pazufloxacin on complicated urinary tract infections
23. Clinical study of pazufloxacin in urological infections
24. T-3762, a new parental fluoroquinolone: Pharmacokinetics and efficacy in respiratory tract infections
25. Information update
26. Yoshitomi's new drugs R and D pipeline
27. In vitro activities of pazufloxacin, a novel injectable quinolone, against bacteria causing infections in obstetric and gynecological patients
28. Therapeutic effects of an injectable new quinolone, pazufloxacin, against polymicrobial infections in the uterine endometritis model
29. Reduced clinical efficacy of pazufloxacin against gonorrhea due to high prevalence of quinolone-resistant isolates with the gyrA mutation. The pazufloxacin STD group
30. Toyaman Chemical: Net loss marked despite 3.8% increase in sales
31. In vitro activity of pazufloxacin, a new fluoroquinolone
32. In vitro activity of pazufloxacin
33. In vitro and in vivo evaluation of pazufloxacin
34. In vitro activity of a new fluoroquinolone
35. A novel new quinolone used orally and parenterally, T-3761
36. In vitro and in vivo antibacterial activities of T-3761, a new fluroquinolone
37. Phase I clinical studyh of pazufloxacin